Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization

项目2：肺癌细胞对SARS-CoV-2感染的易感性和抗体介导的中和作用

• 批准号: 10688382
• 负责人: Adolfo Garcia-Sastre
• 金额: $ 39.6万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10688382
• 关键词: 2019-nCoV; ACE2; Address; Age; Antibodies; Antiviral Agents; Bioinformatics; Biological Assay; COVID-19; COVID-19 pandemic; COVID-19 risk; COVID-19 susceptibility; COVID-19 treatment; COVID-19 vaccine; Cancer Patient; Cells; Clinical; Clinical Sciences; Clinical Trials; Collaborations; Collection; Data; Data Science Core; Data Set; Defect; Development; Disease; Emergency Situation; Epithelial; Epithelial Cells; Evaluation; Exhibits; Future; Genetic Transcription; Genomic approach; Histology; Human; Immune; Immune Sera; Immune response; Individual; Infection; Influenza A virus; Interferons; Kidney; Knowledge; Lung; Lung Neoplasms; Lung diseases; Malignant Neoplasms; Malignant neoplasm of lung; Mediating; Methods; Molecular; Monitor; Monkeys; Natural Immunity; Normal Cell; Normal tissue morphology; Patients; Pharmaceutical Preparations; Population; Predisposition; Preparation; Prevention strategy; Production; Proteins; Resistance; Resources; Risk; SARS-CoV-2 antibody; SARS-CoV-2 exposure; SARS-CoV-2 immunity; SARS-CoV-2 infection; Sample Size; Sampling; Serology; Smoking; Smoking Status; Specificity; Sum; Tissues; Tobacco smoking behavior; Vaccination; Vaccines; Viral; Virus Diseases; Virus Receptors; Virus Replication; acquired immunity; adaptive immunity; airway epithelium; antibody-dependent cell cytotoxicity; antiviral immunity; base; cancer cell; cohort; comorbidity; cytokine; demographics; experimental study; gender diversity; individual patient; individual variation; influenzavirus; insight; inter-individual variation; lung cancer cell; molecular subtypes; mortality; multidisciplinary; neoplastic cell; neutralizing antibody; novel therapeutic intervention; pandemic influenza; patient population; permissiveness; pre-clinical; prevent; protective efficacy; protein expression; receptor; remdesivir; respiratory; respiratory virus; response; screening panel; severe COVID-19; single-cell RNA sequencing; transcriptomics; tumor; vaccine distribution; vaccine strategy

PROJECT 2: ABSTRACT Project 2 is based on evidence that lung cancer patients have higher susceptibility to SARS-CoV-2 infection and increased risk of severe disease and mortality. This increased vulnerability is likely due to a combination of factors, including immune-suppressing effects of the cancer itself or its treatment, age, pre-existing comorbidities, or smoking. Moreover, the potential elevated levels of the receptor for SARS-CoV-2, ACE2 protein, in tumor and tumor-adjacent normal tissues observed in cancer patients and in lungs of tobacco smoking individuals likely contributes to the susceptibility of these patients to SARS-CoV-2. Tumor cells are also known to be more permissive to viral replication due to defects in innate antiviral immunity. The potential for increased SARS-CoV-2 amplification in lung cancer cells might be a major factor contributing to enhanced COVID-19 disease in lung cancer patients. An increased susceptibility to viral infection and replication in lung cells in these patients might also impact the ability of neutralizing antibodies to block viral replication, making lung cancer patients more susceptible to SARS-CoV-2 infection and less able to become immune. Thus, a better understanding of the factors that impact SARS-CoV-2 replication in lung cancer and normal lung cells is needed for devising strategies to reduce the risk of lung cancer patients for severe COVID-19 disease, and for evaluation of the protective efficacy of future SARS-CoV-2 vaccines in these patients. To address these knowledge gaps, in Aim 1 we will identify factors associated with the inter-individual variation in susceptibility to infection by SARS- CoV-2 using an existing unique panel of human lung derived cancer and normal epithelial cells, and relate these factors to key clinical, demographic, and molecular features. We will use a combination of virological and genomics approaches, transcriptomics, and scRNAseq assays. The specificity of the susceptibility to SARS- CoV-2 infection will be evaluated by comparison to other respiratory viruses, such as influenza viruses. In Aim 2, we will characterize the functional activity of antibodies and antivirals in susceptible lung cancer and normal lung epithelial cells. Together with Project 1, we will determine the neutralizing potency of various antisera in susceptible lung cancer cells versus non-cancer respiratory tissue, and antibody dependent cellular cytotoxicity activities of antibodies in lung cancer versus normal lung epithelial cells. Lastly, we will determine the preclinical activity of drugs under clinical trial consideration in lung cancer cells vs. non-cancer respiratory tissue. Successful completion of these aims depend on our multi-disciplinary team, the clinical cohorts, biospecimens and resources provided by the Clinical and Data Sciences Cores and coordinated with overall U54 activities by the Administrative Core. In sum, these studies will provide new information on the determinants of the susceptibility of lung cancer patients to SARS-CoV-2 infection and uncover potential new therapeutic strategies.

项目2：摘要 项目2基于肺癌患者对SARS-CoV-2感染的易感性更高的证据，以及 严重疾病和死亡的风险增加。这种增加的脆弱性很可能是由于 包括癌症本身或其治疗的免疫抑制效应、年龄、既往存在的因素 合并症或吸烟。此外，SARS-CoV-2受体ACE2的潜在水平升高 癌症患者肿瘤及癌旁正常组织和吸烟肺组织中蛋白质的表达 个人可能导致这些患者对SARS-CoV-2的易感性。肿瘤细胞也是已知的 由于先天抗病毒免疫缺陷，对病毒复制更加宽容。增长的潜力 肺癌细胞中SARS-CoV-2的扩增可能是新冠肺炎增强的一个主要因素 肺癌患者的疾病。这些人对病毒感染和肺细胞复制的易感性增加 患者还可能影响中和抗体阻止病毒复制的能力，从而导致肺癌 患者更容易感染SARS-CoV-2，免疫能力较差。因此，一个更好的 需要了解影响SARS-CoV-2在肺癌和正常肺细胞中复制的因素 为设计策略以降低肺癌患者罹患严重新冠肺炎疾病的风险，并进行评估 未来SARS-CoV-2疫苗在这些患者中的保护效果。为了解决这些知识差距， 在目标1中，我们将确定与感染SARS的易感性的个体差异有关的因素： CoV-2使用现有的人类肺癌和正常上皮细胞的独特小组，并将这些联系起来 影响关键临床、人口统计学和分子特征的因素。我们将使用病毒学和 基因组学方法、转录组学和scRNAseq分析。对SARS易感性的特殊性-- 将通过与其他呼吸道病毒，如流感病毒进行比较来评估CoV-2感染情况。在AIM 2，我们将表征抗体和抗病毒药物在易感肺癌和正常人群中的功能活性。 肺上皮细胞。与项目1一起，我们将确定各种抗血清的中和效力 易感肺癌细胞与非癌呼吸道组织的比较及抗体依赖的细胞毒性 肺癌与正常肺上皮细胞中抗体活性的比较。最后，我们将确定临床前 临床试验中考虑的药物在肺癌细胞和非癌症呼吸道组织中的活性。成功 这些目标的完成有赖于我们的多学科团队、临床队列、生物标本和资源 由临床和数据科学核心提供，并与U54的总体活动协调 管理核心。总之，这些研究将为易感性的决定因素提供新的信息。 肺癌患者对SARS-CoV-2感染的研究，并发现潜在的新治疗策略。